Table 4.
Pre-hospital, periprocedural and discharge medications, agiographic findings, and procedural results of the study patients according to the TyG index tertiles
| Variable | T1 n = 257 |
T2 n = 260 |
T3 n = 259 |
P value |
|---|---|---|---|---|
| Medications before admission | ||||
| Aspirin, n (%) | 190 (73.9) | 197 (75.8) | 191 (73.7) | 0.843 |
| P2Y12 inhibitors, n (%) | 104 (40.5) | 111 (42.7) | 95 (36.7) | 0.368 |
| Lipid-lowering drugs, n (%) | 196 (76.3) | 193 (74.2) | 185 (71.4) | 0.454 |
| ACEI/ARBs, n (%) | 81 (31.5) | 88 (33.8) | 85 (32.8) | 0.852 |
| β-blockers, n (%) | 108 (42.0) | 104 (40.0) | 86 (33.2) | 0.097 |
| Insulin, n (%) | 88 (34.2) | 108 (41.5) | 86 (33.2) | 0.099 |
| Oral antidiabetic agents, n (%) | 122 (47.5) | 133 (51.2) | 121 (46.7) | 0.557 |
| Metformin, n (%) | 54 (21.0) | 61 (23.5) | 73 (28.2) | 0.154 |
| Alpha-glucosidase inhibitors, n (%) | 50 (19.5) | 58 (22.3) | 46 (17.8) | 0.422 |
| Sulfonylurea, n (%) | 50 (19.5) | 72 (27.7) | 56 (21.6) | 0.069 |
| Dipeptidyl peptidase 4 inhibitors, n (%) | 6 (2.3) | 4 (1.5) | 2 (0.8) | 0.313 |
| Any antidiabetic treatment, n (%) | 182 (70.8) | 197 (75.8) | 183 (70.7) | 0.334 |
| Periprocedural medications | ||||
| Aspirin, n (%) | 255 (99.2) | 260 (100.0) | 255 (98.5) | 0.113 |
| P2Y12 inhibitors, n (%) | 257 (100.0) | 260 (100.0) | 259 (100.0) | – |
| Unfractionated heparin, n (%) | 213 (82.9) | 213 (81.9) | 212 (81.9) | 0.944 |
| Bivalirudin, n (%) | 34 (13.2) | 32 (12.3) | 34 (13.1) | 0.943 |
| GP IIb/IIIa receptor antagonist, n (%) | 40 (15.6) | 50 (19.2) | 52 (20.1) | 0.371 |
| Medications at discharge | ||||
| Aspirin, n (%) | 255 (99.2) | 260 (100.0) | 255 (98.5) | 0.113 |
| P2Y12 inhibitors, n (%) | 257 (100.0) | 260 (100.0) | 259 (100.0) | – |
| Lipid-lowering drugs, n (%) | 257 (100.0) | 260 (100.0) | 259 (100.0) | – |
| ACEI/ARBs, n (%) | 116 (45.1) | 123 (47.3) | 143 (55.2) | 0.055 |
| β-blockers, n (%) | 189 (73.5) | 190 (73.1) | 183 (70.7) | 0.733 |
| Insulin, n (%) | 86 (33.5) | 94 (36.2) | 84 (32.4) | 0.653 |
| Oral antidiabetic agents, n (%) | 122 (47.5) | 153 (58.8) | 143 (55.2) | 0.030 |
| Metformin, n (%) | 36 (14.0) | 40 (15.4) | 46 (17.8) | 0.495 |
| Alpha-glucosidase inhibitors, n (%) | 76 (29.6) | 103 (39.6) | 99 (38.2) | 0.036 |
| Sulfonylurea, n (%) | 56 (21.8) | 72 (27.7) | 60 (23.2) | 0.260 |
| Dipeptidyl peptidase 4 inhibitors, n (%) | 4 (1.6) | 6 (2.3) | 2 (0.8) | 0.365 |
| Any antidiabetic treatment, n (%) | 172 (66.9) | 197 (75.8) | 189 (73.0) | 0.073 |
| Angiographic findings | ||||
| One-vessel disease, n (%) | 30 (11.7) | 14 (5.4) | 30 (11.6) | 0.020 |
| Two-vessel disease, n (%) | 70 (27.2) | 71 (27.3) | 53 (20.5) | 0.118 |
| LM/three-vessel disease, n (%) | 157 (61.1) | 175 (67.3) | 176 (68.0) | 0.194 |
| Proximal LAD stenosis, n (%) | 117 (45.5) | 143 (55.0) | 134 (51.7) | 0.091 |
| Restenotic lesions, n (%) | 38 (14.8) | 34 (13.1) | 38 (14.7) | 0.823 |
| Chronic total occlusions, n (%) | 53 (20.6) | 64 (24.6) | 59 (22.8) | 0.555 |
| Trifurcation or bifurcation lesions, n (%) | 199 (77.4) | 205 (78.8) | 194 (74.9) | 0.557 |
| Heavy calcification lesions, n (%) | 90 (35.0) | 96 (36.9) | 72 (27.8) | 0.067 |
| Lesions > 20 mm long, n (%) | 133 (51.8) | 155 (59.6) | 158 (61.0) | 0.072 |
| Procedural results | ||||
| Target vessel territory | ||||
| LM, n (%) | 10 (3.9) | 10 (3.8) | 22 (8.5) | 0.027 |
| LAD, n (%) | 132 (51.4) | 120 (46.2) | 130 (50.2) | 0.461 |
| LCX, n (%) | 83 (32.3) | 60 (23.1) | 77 (29.7) | 0.056 |
| RCA, n (%) | 93 (36.2) | 122 (46.9) | 91 (35.1) | 0.010 |
| DES use, n (%) | 225 (87.5) | 226 (86.9) | 195 (75.3) | < 0.001 |
| BRS use, n (%) | 10 (3.9) | 2 (0.8) | 20 (7.7) | < 0.001 |
| DCB use, n (%) | 16 (6.2) | 16 (6.2) | 22 (8.5) | 0.492 |
| Complete revascularization, n (%) | 165 (64.2) | 148 (56.9) | 143 (55.2) | 0.089 |